Tetrahydrocannabinol Has Potential for Treating Agitation in Alzheimer's Disease

Am J Geriatr Psychiatry. 2019 Nov;27(11):1174-1176. doi: 10.1016/j.jagp.2019.05.014. Epub 2019 May 24.

Authors

P B Rosenberg¹, J D Outen¹, H Amjad², M H Burhanullah¹, R Vandrey¹, P J Monette³, B P Forester⁴

Affiliations

¹ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
³ Division of Geriatric Psychiatry, McLean Hospital, Belmont, MA.
⁴ Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Partners HealthCare, Boston, MA.

PMID: 31196620
DOI: 10.1016/j.jagp.2019.05.014

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aggression
Alzheimer Disease*
Dronabinol / analogs & derivatives
Humans
Psychomotor Agitation

Substances

nabilone
Dronabinol